AstraZeneca: new positive data for Enhertu

(CercleFinance.com) - AstraZeneca reports that results from a phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically and clinically significant improvement in progression-free survival (PFS) over standard chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer after one or more lines of endocrine therapy.


Overall survival (OS) data were not mature at the time of analysis; however, Enhertu showed an early trend towards improved OS compared with standard chemotherapy, says the laboratory.

The trial will continue as planned to further evaluate OS and other secondary endpoints.

This data underscores the potential of Enhertu treatment across the spectrum of HR-positive breast cancer, redefining the treatment of metastatic breast cancer, AstraZeneca said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.